Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01381861

NCT01381861
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment
  • Your cancer can be measured using medical scans, with at least one clearly identifiable area of disease
  • You are in good general health and able to carry out daily activities with little or no limitation (confirm with trial site for exact definition)
  • You are expected to live for at least 3 months
  • Any side effects from previous cancer treatments have fully cleared up
  • You do not currently have an active infection that requires antibiotic treatment
  • You previously received at least one chemotherapy treatment that included a platinum-based drug for your original diagnosis
  • You may have received one additional chemotherapy treatment for when the cancer came back
  • Any previous cancer treatments (including hormonal or immune therapies) were stopped at least 3 weeks before joining the trial (hormone replacement therapy may be continued)
  • Your bone marrow, kidneys, liver, nervous system, and blood clotting are all working adequately (confirm with trial site)
  • If you could become pregnant, you have had a negative pregnancy test and agree to use effective contraception

Who may not be able to join:

  • You have previously been treated with the drug TRC105
  • You are currently taking part in another clinical trial involving a treatment
  • You have received any experimental treatment within the past 28 days
  • You have serious wounds, ulcers, or bone fractures that are not healing
  • You have active bleeding or a condition that puts you at high risk of bleeding
  • Your cancer is growing into or around major blood vessels or through the wall of the bowel
  • You have used blood-thinning or clot-dissolving medications within the past 10 days (except small amounts used to keep an IV line open)
  • You have a history of blood clots in a deep vein, unless you have been adequately treated for this (in which case you may still be eligible — confirm with trial site)
  • You have had a stomach ulcer or erosive gastritis in the past 6 months
  • You have a known active hepatitis infection (viral or other)
  • You have a history of cancer or other disease affecting the brain or central nervous system
  • You have significant heart or blood vessel disease
  • You have a known allergy to certain types of laboratory-produced antibodies used in this treatment (confirm with trial site for full details)
  • You are pregnant or breastfeeding
  • You are under 18 years of age
  • You have had or are planning to have a major surgical procedure, open biopsy, or significant injury within 28 days before starting treatment
  • You have had another type of cancer in the past, unless it was a non-melanoma skin cancer or another cancer that was fully treated with no signs of return in the last 3 years
  • You have had uterine cancer diagnosed within the last 5 years, unless it met specific low-risk criteria (confirm with trial site)
  • You have received chemotherapy for any other abdominal or pelvic cancer within the last 5 years (previous breast cancer chemotherapy may be acceptable if finished more than 3 years ago with no recurrence — confirm with trial site)
  • You have previously had radiotherapy to any part of your abdomen or pelvis
  • You have signs of a bowel blockage and need fluids or nutrition given through a drip

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
Tracon Pharmaceuticals Inc.
Registry
clinicaltrials_gov
Start date
1 July 2011
Est. completion
1 August 2012

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Progression-free Survival Rate After 6 Months of Treatment on Study; Proportion of Patients Who Have Objective Tumor Response; Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov